• HMGCS2 Loss Links AECII Lipid Imbalance to Fibrosis

  2026-08-09

  Yang et al. identify injured alveolar type II epithelial cells as a major source of lipid accumulation in bleomycin-associated pulmonary fibrosis and show that released lysophosphatidylcholines can activate lung fibroblasts. Their data connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 regulatory axis, providing a mechanistic framework for studying epithelial–fibroblast crosstalk.

• Liposomal Ce6 PDT Drives Pyroptosis in Breast Cancer

  2026-08-08

  The reference study identifies mitochondrial oxidative damage and caspase-1 signaling as a mechanism by which liposomal chlorin e6 photodynamic therapy induces pyroptosis in breast cancer cells. In mouse models, this treatment also promoted immunogenic cell death and antitumor immune activity, while combination with the immune checkpoint inhibitor BMS202 strengthened tumor control and immune-cell infiltration.

• Alpha-Ketoglutarate Workflows for Immunometabolism

  2026-08-07

  Use alpha-ketoglutarate as a controllable probe for TCA-cycle flux, nitrogen handling, macrophage signaling, and enzyme activity. This workflow connects metabolite dosing with isotope tracing, co-culture assays, and the PDHA1–α-KGA mechanism reported in cholangiocarcinoma research.

• AZD1390: Advancing ATM Kinase Inhibition for Precision Radio

  2026-08-07

  Discover how AZD1390, a potent ATM kinase inhibitor, is revolutionizing cancer research through precision radiosensitization and novel insights into DNA damage response pathways. This article offers a deeper mechanistic and translational analysis, connecting G-quadruplex DNA challenges with advanced assay design.

• Gamithromycin PK/PD in Bovine Respiratory Disease: Site-Spec

  2026-08-06

  This study offers a rigorous pharmacokinetic and pharmacodynamic analysis of gamithromycin in naturally occurring bovine respiratory disease, with a focus on drug concentrations at the pulmonary epithelial lining fluid (PELF) site. The findings clarify exposure–response relationships that are critical for optimizing macrolide antibiotic therapy and inform translational strategies for antibacterial agent development.

• Amplex Red in Translational Redox Biology: Mechanisms and St

  2026-08-06

  This thought-leadership article unpacks the mechanistic underpinnings and translational opportunities of Amplex Red (10-Acetyl-3,7-dihydroxyphenoxazine) in redox biology. By synthesizing the latest scientific findings with strategic assay guidance, we illuminate critical considerations for reliable hydrogen peroxide detection, assay optimization, and data interpretation. Drawing on APExBIO’s product excellence and recent peer-reviewed insights, the article guides researchers beyond protocol basics, addressing pitfalls and proposing actionable solutions for high-impact translational research.

• BMS 599626 Dihydrochloride: EGFR and ErbB2 Inhibitor in Canc

  2026-08-05

  BMS 599626 dihydrochloride stands out as a potent, selective EGFR and ErbB2 inhibitor for dissecting cancer signaling and suppressing tumor growth in translational models. With robust inhibition of HER family kinases and compatibility with advanced assay designs, it enables reproducible, high-impact research in cancer cell proliferation and targeted therapy development.

• Carboxylesterase Interference in Amplex Red H2O2 Assays: Imp

  2026-08-05

  Miwa et al. (2016) discovered that carboxylesterases can convert Amplex Red to resorufin independently of hydrogen peroxide or horseradish peroxidase, introducing substantial artifacts in mitochondrial H2O2 release assays. This finding necessitates critical reassessment of widely used oxidative stress and reactive oxygen species measurement protocols, particularly those relying on Amplex Red fluorescence.

• Artesunate: Strategic Mechanisms for Translational Oncology

  2026-08-04

  Discover how Artesunate, a semi-synthetic artemisinin derivative, is redefining in vitro cancer research. This thought-leadership piece fuses mechanistic depth—spanning ferroptosis, pyroptosis, and AKT/mTOR inhibition—with actionable guidance for translational teams. Drawing on cutting-edge evidence and the latest in vitro protocols, we map a strategy for leveraging Artesunate in small cell lung carcinoma and esophageal squamous cell carcinoma models, while setting a new benchmark for anticancer compound evaluation and workflow reproducibility.

• Ciclesonide in Respiratory Research: Protocols & ERAD Insigh

  2026-08-04

  Ciclesonide and its active metabolite, desisobutyryl-ciclesonide, offer targeted, potent anti-inflammatory action ideal for asthma and allergic rhinitis research. This article details advanced workflows, ERAD-hijacking innovations, and troubleshooting strategies that maximize assay reliability and translational value.

• Polymeric Nanozymes Target Intramacrophage Bacteria in CRC I

  2026-08-03

  This study introduces a self-activatable polymeric nanozyme designed to eradicate Fusobacterium nucleatum within tumor-associated macrophages in colorectal cancer, thereby enhancing the efficacy of CD47 blockade immunotherapy. The findings highlight a novel approach for modulating the tumor microenvironment and overcoming immunotherapeutic resistance.

• Tetracycline Hydrochloride: Applied Protocols in Microbiome

  2026-08-03

  Tetracycline Hydrochloride stands out as a bacteriostatic antibiotic with robust activity against both classic and resistant bacterial strains, enabling precise experimental control in microbiome, cell culture, and protein synthesis inhibition assays. This article demystifies its application through evidence-backed protocols, troubleshooting strategies, and a cross-reference of innovations in rapid, ROS-driven cell death models.

• Novobiocin Sodium: Bridging DNA Gyrase Inhibition to Transla

  2026-08-02

  Explore how Novobiocin Sodium, a classic aminocoumarin antibiotic, is redefining the boundaries of translational research. This article unpacks mechanistic insights into DNA gyrase inhibition, highlights recent anti-parasitic breakthroughs, and provides actionable guidance for researchers studying DNA damage, apoptosis, and antibiotic resistance. Discover how APExBIO's Novobiocin Sodium enables both foundational and cross-kingdom investigations, positioning it as a strategic tool for next-generation host-pathogen and metabolic enzyme protease research.

• CAFs Drive Chemoresistance in Prostate Cancer via ANGPTL4-IQ

  2026-08-01

  This study reveals that cancer-associated fibroblasts (CAFs) promote chemoresistance in prostate cancer by modulating mitochondrial metabolism through the ANGPTL4-IQGAP1 axis. The findings provide mechanistic insight into tumor-stroma interactions and highlight new avenues for targeting metabolic vulnerabilities in chemoresistant prostate cancer.

• Tacrine Hydrochloride Hydrate: Translational Leverage in Neu

  2026-07-31

  Tacrine hydrochloride hydrate (Tetrahydroaminacrine) exemplifies the evolving paradigm in Alzheimer’s disease research, combining mechanistic depth with translational potential. This article frames the biochemical rationale, experimental best practices, and strategic outlook for researchers, drawing on validated literature and industry insights to position APExBIO’s Tacrine hydrochloride hydrate as an indispensable tool for breakthrough discovery.

7804 records 4/521 page Previous Next 12345 下5页 Last page